Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Stock Now Rated “Reduce” by Sell-Side Brokerages

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) have earned a consensus rating of “Reduce” from the twelve research firms that are covering the firm, MarketBeat reports. Four analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and one has given a buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $8.20.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research note on Thursday, October 15th.

Fulcrum Therapeutics Price Performance

Shares of FULC stock opened at $3.68 on Wednesday. Fulcrum Therapeutics has a 12-month low of $2.83 and a 12-month high of $15.74. The business has a 50-day moving average price of $3.78 and a two-hundred day moving average price of $4.65. The firm has a market cap of $280.78 million, a P/E ratio of -3.04 and a beta of 2.63.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.10). As a group, research analysts expect that Fulcrum Therapeutics will post -0.60 EPS for the current fiscal year.

Institutional Investors Weigh In On Fulcrum Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. purchased a new stake in Fulcrum Therapeutics in the second quarter worth $32,297,000. Bank of New York Mellon Corp bought a new position in Fulcrum Therapeutics in the 2nd quarter worth about $566,000. Siren L.L.C. grew its position in Fulcrum Therapeutics by 20.5% during the 1st quarter. Siren L.L.C. now owns 2,350,000 shares of the company’s stock valued at $18,024,000 after purchasing an additional 400,000 shares during the last quarter. Nantahala Capital Management LLC purchased a new stake in Fulcrum Therapeutics during the 2nd quarter valued at about $20,038,646. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in Fulcrum Therapeutics during the 2nd quarter valued at about $2,728,000. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for genetically driven diseases. The company’s research approach is based on selectively modulating gene expression to address the underlying biology of disease rather than targeting individual symptoms.

Fulcrum’s lead investigational program is losmapimod, an oral small-molecule therapy being developed for facioscapulohumeral muscular dystrophy (FSHD), a rare and progressive genetic muscle disorder.